Unique ID issued by UMIN | UMIN000047410 |
---|---|
Receipt number | R000054068 |
Scientific Title | Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients |
Date of disclosure of the study information | 2022/04/06 |
Last modified on | 2022/04/06 10:05:36 |
Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients
Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients
Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients
Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients
Japan |
aortic stenosis
Cardiovascular surgery |
Others
NO
In recent years, the number of new patients undergoing hemodialysis (HD) has been increasing, primarily because of the aging population and the evolution of HD techniques. The number of annual deaths has also been increasing. According to a report by the Japanese Society for HD therapy, heart failure (HF) was the most common cause of death in 2019 (22.7%), followed by infections (21.5%), malignancies (8.7%), cerebrovascular disease (5.7%), and myocardial infarction (MI) (3.9%). The frequencies of calcification associated with intimal atherosclerosis and tunica media are high in HD patients, and atherosclerosis and calcification are risk factors for cardiovascular disease. Moreover, ectopic calcification reportedly progresses more rapidly in HD patients than it does in non-HD patients. The incidence of aortic stenosis (AS) in HD patients has been increasing annually and is a leading cause of death. In surgical aortic valve replacement (SAVR), surgical mortality and morbidity rates are also higher in HD patients than in non-HD patients. Elucidating the prognostic factors is important to improve the prognosis of SAVR in HD patients. Therefore, in this study, we investigated the preoperative and postoperative risk factors for mid-term mortality following SAVR with bioprostheses (SAVR-BP) in HD patients.
Efficacy
Five-year mortality risk factors
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
surgical aortic valve replacement with bioprostheses
Not applicable |
Not applicable |
Male and Female
Patients who underwent SAVR-BP for HD patients with aortic stenosis at Dokkyo Medical University Hospital between July 2009 and December 2020 included.
patients who deemed inappropriate for aortic valve repair.
60
1st name | Ikuko |
Middle name | |
Last name | Shibasaki |
Dokkyo Medical University School of Medicine
Department of Cardiac and Vascular Surgery
321-0293
880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi,Japan
0282861111
sibasaki@dokkyomed.ac.jp
1st name | Ikuko |
Middle name | |
Last name | Shibasaki |
Dokkyo Medical University School of Medicine
Department of Cardiac and Vascular Surgery
321-0293
880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi,Japan
0282861111
sibasaki@dokkyomed.ac.jp
Dokkyo Medical University School of Medicine
Dokkyo Medical University School of Medicine
Self funding
Dokkyo Medical University School of Medicine
880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, Japan
0282-86-1111
sibasaki@dokkyomed.ac.jp
NO
2022 | Year | 04 | Month | 06 | Day |
Unpublished
57
Completed
2021 | Year | 09 | Month | 01 | Day |
2021 | Year | 08 | Month | 20 | Day |
2021 | Year | 10 | Month | 01 | Day |
2023 | Year | 03 | Month | 31 | Day |
2022 | Year | 04 | Month | 06 | Day |
2022 | Year | 04 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054068